



HEALTH EFFECTS DIVISION
 UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

DEC 16 1997

FILE

OFFICE OF
 PREVENTION, PESTICIDES AND
 TOXIC SUBSTANCES

MEMORANDUM

SUBJECT: ID. No. 080803, Atrazine Articles

DP Barcode #: D239246
 Record No. : S530467

FROM: Melba S. Morrow, D.V.M. *MSM 12/7/97*
 Registration Action Branch I
 Health Effects Division (H7509C)

TO: Jeffrey Morris/Robert McNally Team 60
 SRRD

THRU: Ed Zager *EZager*
 Branch Chief
 Registration Action Branch I
 Health Effects Division (H7509C)

CONCLUSIONS: The two articles provided to HED which pertained to atrazine do not require a toxicology review. The study by Safe, et. al., which utilizes MCF-7 human breast cells does not provide new information on the activity of atrazine in the formation of mammary tumors. In his study, atrazine reduced estradiol 2-hydroxylase activity; however, Dr. Safe found no correlation between activity of the enzyme estradiol 2-hydroxylase and the carcinogenic potential of several compounds, including atrazine.

The consensus panel report focused on all of the evidence that was available which served to elucidate a mode of action for atrazine in the formation of mammary tumors. The studies that the panel highlighted were those that we addressed in our weight of the evidence document provided at the cancer SARC on August 12, 1997. Other information contained in the report provided a history of studies that were conducted earlier and several of the hypotheses surrounding the mechanism of action of atrazine that have been dispelled.

It is my opinion that the risk assessment should address the manner in which the cancer risk will be characterized, given the mode of action of atrazine. A report from HED, capturing the decisions of the Cancer SARC should be finalized in the near future.



13544

R149595

Chemical: Atrazine

PC Code:
080803

HED File Code: 11000 Chemistry Reviews
Memo Date: 12/16/1997
File ID: DPD239246
Accession #: 000-00-0120

HED Records Reference Center
6/22/2007